Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.

The Journal of clinical investigation - 1 Oct 2020

Biernacki Melinda A, Foster Kimberly A, Woodward Kyle B, Coon Michael E, Cummings Carrie, Cunningham Tanya M, Dossa Robson G, Brault Michelle, Stokke Jamie, Olsen Tayla M, Gardner Kelda, Estey Elihu, Meshinchi Soheil, Rongvaux Anthony, Bleakley Marie

Abstract excerpt

Proteins created from recurrent fusion genes like CBFB-MYH11 are prevalent in acute myeloid leukemia (AML), often necessary for leukemogenesis, persistent throughout the disease course, and highly leukemia specific, making them attractive neoantigen targets for immunotherapy. A nonameric peptide derived from a prevalent CBFB-MYH11 fusion protein was found to be immunogenic in HLA-B*40:01+ donors. High-avidity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Leukocytes

Share to Mutation

Share to Myosin Heavy Chains

Share to Oncogene Proteins, Fusion

Source

Open in PubMed Open full text

Identifiers

PMID: 32831296
DOI: 10.1172/JCI137723
PMCID: PMC7524498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.PMID 32831296Read ↗

Identification of specific T-cell response and T-cell receptor targeting shared neoantigen for acute myeloid leukemia.Semantic proximity Read ↗

Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.Semantic proximity Read ↗

Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy.Semantic proximity Read ↗

Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Cryptic leukemia antigens share homology with microbial epitopes and stimulate T-cell responses in healthy donorsSemantic proximity Read ↗

Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.Semantic proximity Read ↗

Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.Semantic proximity Read ↗

An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AMLSemantic proximity Read ↗

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMTSemantic proximity Read ↗

EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AMLSemantic proximity Read ↗

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?Semantic proximity Read ↗

SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.